|
Volumn 18, Issue 1, 2005, Pages 1-16
|
Tumor angiogenesis and molecular target therapy in ovarian carcinomas.
a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANGIOGENIC FACTOR;
ANGIOGENIC PROTEIN;
ANGIOZYME;
BEVACIZUMAB;
GELATINASE A;
MONOCLONAL ANTIBODY;
PEPTIDE;
RIBOZYME;
SPON1 PROTEIN, HUMAN;
VASCULOTROPIN A;
ANIMAL;
CANCER INVASION;
CARCINOMA;
CELL CULTURE;
CELL PROLIFERATION;
DRUG ANTAGONISM;
FEMALE;
GENE EXPRESSION REGULATION;
GENE THERAPY;
GENETICS;
HUMAN;
METASTASIS;
NEOVASCULARIZATION (PATHOLOGY);
OVARY TUMOR;
PATHOLOGY;
PHYSIOLOGY;
REVIEW;
VASCULARIZATION;
ANGIOGENESIS INDUCING AGENTS;
ANGIOGENESIS INHIBITORS;
ANGIOGENIC PROTEINS;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CARCINOMA;
CELL PROLIFERATION;
FEMALE;
GENE EXPRESSION REGULATION, NEOPLASTIC;
GENE THERAPY;
HUMANS;
MATRIX METALLOPROTEINASE 2;
NEOPLASM INVASIVENESS;
NEOPLASM METASTASIS;
NEOVASCULARIZATION, PATHOLOGIC;
OVARIAN NEOPLASMS;
PEPTIDES;
RNA, CATALYTIC;
TUMOR CELLS, CULTURED;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
MLCS;
MLOWN;
|
EID: 27744539151
PISSN: 09147470
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1749-0774.2005.tb00052.x Document Type: Review |
Times cited : (22)
|
References (42)
|